Literature DB >> 35259252

SARS-CoV-2 vaccination and immune thrombotic thrombocytopenic purpura.

Hridaya Shah1, Ann Kim2, Senthil Sukumar3, Marshall Mazepa4, Ruhail Kohli5, Evan M Braunstein6, Robert A Brodsky6, Spero Cataland3, Shruti Chaturvedi6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35259252      PMCID： PMC8906888          DOI： 10.1182/blood.2022015545

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   25.476


× No keyword cloud information.
  21 in total

1.  Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi-institutional study.

Authors:  Francesca Schieppati; Laura Russo; Marina Marchetti; Luca Barcella; Maurizio Cefis; Patricia Gomez-Rosas; Gloria Caldara; Monica Carpenedo; Mariella D'Adda; Alessandro Rambaldi; Chiara Savignano; Atto Billio; Massimiliano Bruno Franco; Vincenzo Toschi; Anna Falanga
Journal:  Am J Hematol       Date:  2020-04-29       Impact factor: 10.047

2.  Acute thrombotic thrombocytopenic purpura after pneumococcal vaccination.

Authors:  Yuki Kojima; Haruhiko Ohashi; Tomonobu Nakamura; Hiroyuki Nakamura; Hideyuki Yamamoto; Yasuhiko Miyata; Hiroatsu Iida; Hirokazu Nagai
Journal:  Blood Coagul Fibrinolysis       Date:  2014-07       Impact factor: 1.276

3.  The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency.

Authors:  D R Terrell; L A Williams; S K Vesely; B Lämmle; J A K Hovinga; J N George
Journal:  J Thromb Haemost       Date:  2005-07       Impact factor: 5.824

Review 4.  Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).

Authors:  Tom T Shimabukuro; Michael Nguyen; David Martin; Frank DeStefano
Journal:  Vaccine       Date:  2015-07-22       Impact factor: 3.641

5.  Refractory thrombotic thrombocytopenic purpura following influenza vaccination.

Authors:  P J Dias; S Gopal
Journal:  Anaesthesia       Date:  2009-04       Impact factor: 6.955

6.  First report of a de novo iTTP episode associated with an mRNA-based anti-COVID-19 vaccination.

Authors:  Sévérine de Bruijn; Marie-Berthe Maes; Laure De Waele; Karen Vanhoorelbeke; Alain Gadisseur
Journal:  J Thromb Haemost       Date:  2021-07-05       Impact factor: 16.036

7.  Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia.

Authors:  Andreas Greinacher; Kathleen Selleng; Raghavendra Palankar; Jan Wesche; Stefan Handtke; Martina Wolff; Konstanze Aurich; Michael Lalk; Karen Methling; Uwe Völker; Christian Hentschker; Stephan Michalik; Leif Steil; Alexander Reder; Linda Schönborn; Martin Beer; Kati Franzke; Andreas Büttner; Boris Fehse; Evi X Stavrou; Chandini Rangaswamy; Reiner K Mailer; Hanna Englert; Maike Frye; Thomas Thiele; Stefan Kochanek; Lea Krutzke; Florian Siegerist; Nicole Endlich; Theodore E Warkentin; Thomas Renné
Journal:  Blood       Date:  2021-12-02       Impact factor: 25.476

8.  Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine.

Authors:  Johannes Ruhe; Ulf Schnetzke; Karim Kentouche; Florian Prims; Michael Baier; Konstantin Herfurth; Mandy Schlosser; Martin Busch; Andreas Hochhaus; Gunter Wolf
Journal:  Ann Hematol       Date:  2021-07-26       Impact factor: 3.673
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.